Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Inclusion Criteria: * Measurable unresectable Stage III or Stage IV melanoma * ECOG Performance Status 0 or 1 * 4 weeks or greater since treatment * Must have recovered from any acute toxicity associated with prior therapy * Life expectancy of greater than 12 weeks * 18 years of age or older * Laboratory values as outlined in protocol * Negative screening tests for HIV, active Hepatitis B and Hepatitis C * Patients who received prior therapy with anthracyclines should have a baseline MUGA or echo with a normal ejection fraction Exclusion Criteria: * CNS metastases * Pregnant or nursing women * Prior therapy with bevacizumab or ipilimumab * Active infection * Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic autoimmune disease * Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix * Any underlying medical condition which, in the principal investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events * Any concurrent medical condition requiring the use of systemic steroids * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke of transient ischemic attack within 6 months prior to study enrollment * Significant known vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer or bone fracture * Proteinuria at screening * Known hypersensitivity to any component of bevacizumab * History of hemoptysis within 3 months prior to study enrollment * Current, ongoing treatment with full-dose warfarin or its equivalent * Current or recent (within 10 days of enrollment) use of aspirin (\>325mg/day) or chronic use of other NSAIDs * Medications that inhibit platelet function * Known involvement of melanoma within gastrointestinal tract * Ulcerated skin lesions